MP33-20 ADAR1 IS HIGHLY EXPRESSED IN PRIMARY PROSTATE CANCER AND CORRELATED WITH CD8+ T-LYMPHOCYTES DENSITY

Abstract

You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology I (MP33)1 Sep 2021MP33-20 ADAR1 IS HIGHLY EXPRESSED IN PRIMARY PROSTATE CANCER AND CORRELATED WITH CD8+ T-LYMPHOCYTES DENSITY Paolo Vota, Fabio Grizzi, Pieve Emanuele, Matteo Zanoni, Giovanni Toia, Mattia Nicola Sangalli, Cinzia Mazzieri, Alberto Mandressi, Davide Maffei, Nicolò Buffi, Giovanni Lughezzani, Pieve Emanuele, Massimo Lazzeri Rozzano, Giorgio Guazzoni, Pieve Emanuele, and Gian Luigi Taverna Paolo VotaPaolo Vota More articles by this author , Fabio GrizziFabio Grizzi More articles by this author , Pieve EmanuelePieve Emanuele More articles by this author , Matteo ZanoniMatteo Zanoni More articles by this author , Giovanni ToiaGiovanni Toia More articles by this author , Mattia Nicola SangalliMattia Nicola Sangalli More articles by this author , Cinzia MazzieriCinzia Mazzieri More articles by this author , Alberto MandressiAlberto Mandressi More articles by this author , Davide MaffeiDavide Maffei More articles by this author , Nicolò BuffiNicolò Buffi More articles by this author , Giovanni LughezzaniGiovanni Lughezzani More articles by this author , Pieve EmanuelePieve Emanuele More articles by this author , Massimo Lazzeri RozzanoMassimo Lazzeri Rozzano More articles by this author , Giorgio GuazzoniGiorgio Guazzoni More articles by this author , Pieve EmanuelePieve Emanuele More articles by this author , and Gian Luigi TavernaGian Luigi Taverna More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002042.20AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: It is now recognized that the evolution of cancer cells is dependent by genetic or epigenetic alterations. However, this concept has recently been challenged by another mode of nucleotide alteration, RNA editing, which is frequently upregulated in cancer(1) RNA editing is a biochemical process in which either Adenosine or Cytosine is deaminated by a group of RNA editing enzymes including ADAR (Adenosine deaminase; RNA specific) The result of RNA editing is usually adenosine to inosine (A-to-I) or cytidine to uridine (C-to-U) transition, which can affect protein coding, RNA stability, splicing and microRNA-target interactions(2). The aim of this study was to preliminarily investigate the expression of ADAR1 in a series of prostate cancer specimens and benign prostatic hyperplasia (BPH) following transurethral resection of the prostate (TURP). METHODS: Sixty prostate specimens were investigated. Fifty specimens were diagnosed as prostate carcinoma and 15 as benign prostate hyperplasia. The samples were fixed in 10% formaldehyde and paraffin-embedded. Two-micrometer thick sections were cut and processed for immunohistochemistry with primary antibodies raised against ADAR1 (SantaCruz Biotechnology, Dallas, TX, USA) or CD8+ T-lymphocytes (Dako, Milan, Italy). 3,3’-Diaminobenzidine tetrahydrochloride was used as a chromogen to yield brown reaction products. To quantify the surface covered by infiltrating CTLs each histological section was digitized using an automated image analysis system with incorporated ad hoc constructed image analysis software. The system automatically selected the surface covered by the CTL on the basis of red, green and blue (RGB) color segmentation. RESULTS: ADAR1 up-regulation was heterogeneously detected in a high percentage of prostate cancer tissues, but to a much lesser extent in adjacent non-malignant tissues or tissue affected by BPH (p<0.001). Prostate cancers with high ADAR1 expression exhibited high tumor-infiltrating CD8 + T lymphocyte. ADAR expression is associated with several diseases including cancer, neurological disorders, metabolic diseases, viral infections, and autoimmune disorders. CONCLUSIONS: This study first shows that ADAR1 is highly expressed in a high percentage of prostate cancer tissues, but to a much lesser extent in adjacent non-malignant tissues or tissue affected by benign prostatic hyperplasia. Additionally, prostate cancers with high ADAR1 expression exhibited high tumor-infiltrating CD8 + T lymphocyte. Our findings indicated that ADAR1 might play an important role in the occurrence, progression, and prognosis of prostate cancer, and open new ways for the development of new and more effective immunological therapeutic strategies. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e614-e615 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Paolo Vota More articles by this author Fabio Grizzi More articles by this author Pieve Emanuele More articles by this author Matteo Zanoni More articles by this author Giovanni Toia More articles by this author Mattia Nicola Sangalli More articles by this author Cinzia Mazzieri More articles by this author Alberto Mandressi More articles by this author Davide Maffei More articles by this author Nicolò Buffi More articles by this author Giovanni Lughezzani More articles by this author Pieve Emanuele More articles by this author Massimo Lazzeri Rozzano More articles by this author Giorgio Guazzoni More articles by this author Pieve Emanuele More articles by this author Gian Luigi Taverna More articles by this author Expand All Advertisement Loading ...